Treatment Response And Clinical Outcomes Of Well-Differentiated High-Grade Neuroendocrine Tumors To 177lu-Dotatate.

Kelley Lauren Coffman,Lisa Bodei,Tiffany Le,Ye Choi,Joanne F. Chou,Marinela Capanu,Mark Dunphy,Josef J. Fox,Ravinder K Grewal,Ryan Reddy,Christopher Riedl,Heiko Schöder,Diane Lauren Reidy,Nitya Prabhakar Raj

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 3|浏览14

暂无评分

摘要

368Background: 177Lu-DOTATATE is an approved therapy for somatostatin receptor (sstr) positive gastroenteropancreatic neuroendocrine tumors (NETs). There are little data available on response and o...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要